Evidence map›Paper›PMID 41190967›Full record

ArticleCytotherapy2026

Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies.

Alexandra Dreyzin, Anne Marijn Kramer, Bonnie Yates, Hao-Wei Wang, Bita Sahaf, Constance Yuan, Dorota Klysz, Ramya Tunuguntla, Zachary Ehlinger, Skyler Reitberg and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Alexandra DreyzinCenter for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Anne Marijn KramerCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, California, USA.
Bonnie YatesPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Hao-Wei WangLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Bita SahafCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, California, USA.
Constance YuanLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Dorota KlyszCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Laboratory for Cell and Gene Medicine, Stanford University, Stanford, California, USA.
Ramya TunuguntlaCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Laboratory for Cell and Gene Medicine, Stanford University, Stanford, California, USA.
Zachary EhlingerCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, California, USA.
Skyler ReitbergCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA.
Serifat AdebolaImmunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Angela SuPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Risa Ebina-ShibuyaPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Medical Science and Innovation, SiRIUS Institute of Medical Research, Tohoku University, Sendai, Japan and Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Dongya JiaImmunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Sooraj AcharImmunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Sunita PatilCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, California, USA.
Kathryn MartinCenter for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Nikeshan JeyakumarCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, California, USA.
Kara L DavisCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California, USA.
Terry FryDepartment of Pediatrics and Immunology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Aurora, Colorado, USA.
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California, USA.
Naomi TaylorPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gregoire Altan-BonnetImmunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Steven HighfillCenter for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Steven FeldmanCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Laboratory for Cell and Gene Medicine, Stanford University, Stanford, California, USA.
David F StroncekCenter for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Christopher ChienPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Liora Michal SchultzCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California, USA.
Matthew J FrankCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, California, USA.
Lori S MufflyCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, California, USA.
Haneen ShalabiPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Sneha RamakrishnaCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California, USA. Electronic address: ramakrs@stanford.edu.
Nirali N ShahPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: nirali.shah@nih.gov.

Funding

Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1M
Immunotherapeutic approaches to treat pediatric hematologic malignanciesZIABC011823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$6.1M
Defining Pre-treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune ProfilingK08CA267057 · NCI · STANFORD UNIVERSITY · PI Sneha Ramakrishna · 2022 to 2026
$1.1M
Intramural NIH HHS ZIA BC011823NCI NIH HHS K08 CA267057NCI NIH HHS U54 CA232568
6 · The paper itself

Abstract

As use of chimeric antigen receptor (CAR) T-cells continues to grow, there is increasing interest in utilizing automated manufacturing systems as a mechanism to support decentralized manufacturing and increase access. However, most FDA approved CAR T-cell therapies are manufactured using traditional bag culture methodologies. Thus, understanding how different manufacturing platforms may impact outcomes is imperative. With parallel trials of CD22 CAR T-cells conducted in patients with B-cell acute lymphoblastic leukemia using a uniform vector but two different manufacturing strategies - either bag-culture (BC) or Prodigy - we were able to compare outcomes. Across 57 patients, 41 received BC cells and 16 received Prodigy-based cells. No significant differences in response rates or incidence of CAR-associated toxicities were observed between cohorts, although the BC cohort had slightly higher rates of severe CRS and IEC-HS. Peak ferritin and C-reactive protein levels were higher in the BC cohort. CAR T-cell expansion was similar, except for patients who had extramedullary disease with low bone marrow disease burden (n = 6 from each group), for whom BC-manufactured cells had greater expansion. In summary, while efficacy across both platforms was comparable, lower inflammatory markers in those who received Prodigy manufactured CAR T-cells suggest changes in the infusion product.

Indexed as

Immunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2T-LymphocytesAdolescentAdultAgedFemaleHumansMaleMiddle AgedTreatment OutcomeCD22 protein, humanReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2CAR T-cell expansionCAR T-cellsCD22Cell Therapyclinical trialsclosed-system manufacturingleukemiamanufacturingpediatric Oncologyprodigy

Identifiers

PMID41190967
PMCPMC12997837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.